CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma

Objective To evaluate the efficacy of percutaneous interstitial implantation with 125I seeds for recurrent patients of postoperative non-small cell lung carcinoma (NSCLC) guided by CT.Methods Thirty-two NLCLC patients were verified by biopsy pathology.Prescribed dose was 90 Gy.The percutaneous interstitial implantation of 125I seeds treatment was guided by CT.The carcinoma were scanned by CT and compared before and 6 months after treatment.Then judge the curative effect accerding to the curative standard put forward by World Health Organization.All the patients were folluwed-up for 6 to 72 months, mean 24 months.Results The mean radioactive dose of therapy group was 153.7 Gy, D90 was 93.5 Gy.Among the 32 follow-up cases, the complete and partial remission rate was 90.6％, and no major complications.One and two year survival rate were 87％ and 73％, mean survival was 35 months.Conclusion Percutaneous interstitial implantation with 125I seeds for recurrent patients of postoperative NSCLC guided by CT is a valid, minimally invasive and efficient method. Key words: Carcinoma, non-small-cell lung;  Iodine radioisotopes;  Brachytherapy;  Tomography, X-ray computed;  Neoplasm recurrence, local